Guardant Health Leans on Patrick Dempsey for Colorectal Cancer Awareness Campaign
Event summary
- Guardant Health launched an emotional tribute video featuring actor Patrick Dempsey to raise awareness about colorectal cancer screenings.
- The campaign highlights the Shield blood test, which has been FDA-approved and included in ACS and NCCN guidelines.
- Shield has shown over 90% patient completion rates in real-world testing with approximately 200,000 patients tested.
- Colorectal cancer is the second leading cancer killer in the U.S. and the top cancer killer for adults under 50.
The big picture
Guardant Health's campaign underscores the growing importance of non-invasive, blood-based screening tests in preventive oncology. The company is positioning Shield as a key player in addressing the rising burden of colorectal cancer, particularly among younger adults. This strategic move aligns with broader industry trends toward personalized and early detection methods in cancer care.
What we're watching
- Market Adoption
- How Guardant Health will scale the adoption of Shield among primary care physicians and patients.
- Regulatory Compliance
- Whether Shield can maintain its FDA approval status while expanding its market reach.
- Competitive Positioning
- The pace at which Guardant Health can differentiate Shield from other colorectal cancer screening options.
Related topics